Genmab — Marts 2023
-
New RYBREVANT
(amivantamab-vmjw) Data Showed Long-Term Clinical Response and Safety in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Who Have Failed Prior Platinum-Based Chemotherapy https://www.jnj.com/new-rybrevant-amivantamab-vmjw-data-showed-long-term-clinical-response-and-safety-in-patients-with-advanced-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations-who-have-failed-prior-platinum-based-chemotherapy -
Ja, det lyder fint med aktietilbagekøb. Det har Genmab gjort flere gange. Men jeg kan ikke mindes, at der er blevet annulleret bare een eneste aktie af disse. Men, det er jo gået rimeligt for os menige aktionærer alligevel.
-
Et opkøb af Genmab ser jeg ikke som sandsynligt. Dertil har de, meget vidtgående, tildelingsprogrammer til direktion og bestyrelse for stor betydning. I givet fald, skulle der være tale om et direkte fjendtligt tilbud. Jeg tror, at det er utopi. Sugerørerne er for gode. Men spørgsmålet er vel også, om vi almindelige aktionærer, på sigt ville blive bedre stillet ved et opkøb?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
